C4 Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CCCC research report →
Companywww.c4therapeutics.com
C4 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.
- CEO
- Andrew J. Hirsch
- IPO
- 2020
- Employees
- 110
- HQ
- Watertown, MA, US
Price Chart
Valuation
- Market Cap
- $270.45M
- P/E
- -3.97
- P/S
- 7.76
- P/B
- 1.76
- EV/EBITDA
- -2.47
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 94.83%
- Op Margin
- -326.56%
- Net Margin
- -297.76%
- ROE
- -50.68%
- ROIC
- -36.95%
Growth & Income
- Revenue
- $35.95M · 1.02%
- Net Income
- $-104,994,000 · 0.31%
- EPS
- $-1.27 · 16.45%
- Op Income
- $-104,489,000
- FCF YoY
- -51.98%
Performance & Tape
- 52W High
- $3.95
- 52W Low
- $1.21
- 50D MA
- $2.88
- 200D MA
- $2.51
- Beta
- 2.78
- Avg Volume
- 3.46M
Get TickerSpark's AI analysis on CCCC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | Anderson Kenneth Carl | other | 4,259 |
| Apr 1, 26 | GROGAN DONNA ROY | other | 5,370 |
| Feb 13, 26 | Boyle Scott N | other | 200,000 |
| Feb 13, 26 | Boyle Scott N | other | 5,000 |
| Feb 14, 26 | Boyle Scott N | other | 20,950 |
| Feb 13, 26 | Boyle Scott N | other | 1,735 |
| Feb 14, 26 | Boyle Scott N | other | 7,269 |
| Feb 14, 26 | Mahaney Paige | other | 7,050 |
| Feb 13, 26 | Mahaney Paige | other | 240,000 |
| Feb 14, 26 | Mahaney Paige | other | 2,446 |
Our CCCC Coverage
We haven't published any research on CCCC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CCCC Report →